# Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

Study · id `cardio:ct-nct04591808` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04591808](<https://clinicaltrials.gov/study/NCT04591808>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04591808

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 146 participants.

## Technical summary

Registry record NCT04591808. Randomized; double masking; primary purpose treatment. Start 2021-09-09 (actual); primary completion 2022-04-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 146 participants (enrolled count; ClinicalTrials.gov record NCT04591808, source copy `cardio:ctgov-nct04591808-2023-10-18`, retrieved 2026-10-26)
- Started: 2021-09-09 (actual) (ClinicalTrials.gov record NCT04591808, source copy `cardio:ctgov-nct04591808-2023-10-18`, retrieved 2026-10-26)
- Primary completion: 2022-04-08 (actual) (ClinicalTrials.gov record NCT04591808, source copy `cardio:ctgov-nct04591808-2023-10-18`, retrieved 2026-10-26)
- Completion: 2022-04-08 (actual) (ClinicalTrials.gov record NCT04591808, source copy `cardio:ctgov-nct04591808-2023-10-18`, retrieved 2026-10-26)
- Countries: Georgia; Russia; Ukraine (ClinicalTrials.gov record NCT04591808, source copy `cardio:ctgov-nct04591808-2023-10-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04591808-2023-10-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
- Condition: Dyslipidemias
- Condition: Hypertension
- Intervention (Drug): Atorvastatin/Perindopril
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Perindopril
- Lead sponsor: Institut de Recherches Internationales Servier
- Lead sponsor class: OTHER
- Collaborator: ADIR, a Servier Group company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)

## Provenance

Content hash: 0fd9490137ae334abb8f83ab4ad43a36b44d7fca693af3987983050d3409e84f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
